Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Celgene Corporation    CELG   US1510201049


SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Celgene Corporation : Celgene 1st-Quarter Net Down 4.1% Amid Increased Costs

04/25/2013 | 08:25am US/Eastern
   By Ben Fox Rubin 

Celgene Corp.'s (CELG) first-quarter profit fell 4.1% as the drug maker saw higher expenses offset stronger revenue from its Revlimid and Vidaza drugs.

The company raised its full-year guidance to a range of $5.55 to $5.65 a share in adjusted earnings from $5.50 to $5.60. It also backed its full-year product sales outlook.

Celgene has continued to post improved revenue, with its flagship blood-cancer treatment Revlimid grabbing more market share and sales of Vidaza, a blood-cancer treatment that lost patent exclusivity in May 2011, continuing to rise in the face of generic competition. The biopharmaceutical company also is expanding its core hematology franchise and building out new product lines in cancer and psoriasis as part of a strategy to achieve $12 billion in product sales by 2017.

Celgene reported a profit of $384.9 million, or 89 cents a share, down from $401.5 million, or 90 cents, a year earlier. Excluding items such as stock-based compensation, per-share earnings rose to $1.37 from $1.08.

Revenue grew 15% to $1.46 billion.

Analysts polled by Thomson Reuters had most recently forecast earnings of $1.35 a share on revenue of $1.47 billion.

Total costs and expenses rose 27%.

Revlimid sales were up 16% to $1 billion while Vidaza sales rose 10% to $204 million.

Shares closed Wednesday at $118.28 and were down 0.2% premarket. The stock has gained 51% so far this year.

Write to Ben Fox Rubin at

Order free Annual Report for Celgene Corp.

Visit or call +44 (0)208 391 6028

React to this article
01:14a CELGENE : Secures Approval from the European Commission for Oral Otezla
01/23 CELGENE : Announces 2015 and Long-Term Financial Outlook and Preliminary 2014 Re..
01/23 CELGENE : Receives Positive CHMP Opinion for ABRAXANE® for First-Line Treatment ..
01/22 CELGENE : Halozyme Appoints Jean-Pierre Bizzari, M.D. To Board Of Directors
01/22 CELGENE : Gets Approval by the European Commission for Oral Otezla
01/21 CELGENE : Provides 2015 and Long-Term Financial Outlook and Preliminary 2014 Res..
01/21 CELGENE : Posts 2015 and Long-Term Financial Outlook and Preliminary 2014 Result..
01/19 CELGENE : European Commission grants marketing authorisation for Celgene's OTEZL..
01/16 CELGENE : EU Oks new Celgene pill for psoriasis, psoriatic arthritis
01/16 CELGENE : Oral OTEZLA® (apremilast) Approved by the European Commission for the ..
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes